Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE; ZIDOVUDINE; ABACAVIR

LAMIVUDINE; ZIDOVUDINE; ABACAVIR

Standard Dose
150MG; 300MG; 300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE; ZIDOVUDINE; ABACAVIR is listed in Drugs@FDA under application 021944 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE; ABACAVIR Form and strength TABLET; ORAL - 150MG; 300MG; 300MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2006-07-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; ZIDOVUDINE; ABACAVIR is listed in Drugs@FDA under application 021944 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE; ABACAVIR Form and strength TABLET; ORAL - 150MG; 300MG; 300MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2006-07-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.